Companies / BOC Sciences / dinutuximab
BOC Sciences

dinutuximab | BOC Sciences

Dinutuximab is an anti-GD2 monoclonal antibody. Dinutuximab beta was approved for the treatment of patients with high-risk neuroblastoma. In combination with interleukin-2, dinutuximab beta is used to treat those who have not achieved a complete response after first-line therapy.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.